Genenta Science (NASDAQ:GNTA) Stock Jumps 2.5% – Should You Buy?

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) shares were up 2.5% during mid-day trading on Thursday. The company traded as high as $0.62 and last traded at $0.62. 152,582 shares changed hands during mid-day trading, an increase of 230% from the average daily volume of 46,208 shares. The stock had previously closed at $0.6050.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Genenta Science presently has a consensus rating of “Sell”.

Genenta Science Price Performance

The stock’s fifty day moving average is $0.79 and its two-hundred day moving average is $1.04.

About Genenta Science

Genenta Science S.p.A. is a biotechnology company focused on developing cell-based gene therapies for cancer. The company’s approach is designed to use a patient’s own hematopoietic stem cells, modified outside the body, to deliver therapeutic proteins directly within the tumor microenvironment.

Genenta’s lead platform, TEMFERON, uses genetically engineered stem cells to produce interferon alpha in tumors. This strategy is intended to concentrate treatment at the disease site while limiting the systemic toxicity associated with administering interferon alpha throughout the body.